1600527-99-8

Upstream product

• 37131-87-6 5-bromo-2-pyrimidinecarboxylic acid 
• 766-83-6 m-chlorophenylacetylene 

Downstream Products

• 1600527-96-5 (3,3-dimethyl-morpholin-4-yl)-[5-(3-chloro-phenylethynyl)-pyrimidin-2-yl]-methanone 

Relevant academic research and scientific papers

ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH; R1 is hydrogen, fluoro or chloro; and R2 is hydrogen or lower alkyl; or to a pharmaceutically acceptable acid addition salt thereof. It has now surprisingly been found that the compounds of general formula (I) are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

ETHYNYL DERIVATIVES AS MODULATORS OF MGLUR5 RECEPTOR ACTIVITY

The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula (I) are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD)

ETHYNYL DERIVATIVES AS MODULATORS OF MGLUR5 RECEPTOR ACTIVITY

The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).